Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
782 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04720209 | Taking AIM at Breast Cancer | active not recruiting | N/A | 102 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | not yet recruiting | Phase 1 / Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03668340 |
| AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma |
| active not recruiting |
| Phase 2 |
| 49 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT07729150 | Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes(ReduceHEAT) | recruiting | N/A | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03716180 | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | active not recruiting | Phase 1 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04417062 | Olaparib With Ceralasertib in Recurrent Osteosarcoma | active not recruiting | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04584255 | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | active not recruiting | Phase 2 | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02537613 | A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03668223 | The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer(PRISM-AC) | completed | N/A | 269 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05121558 | The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)(YCT) | active not recruiting | N/A | 227 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06202820 | CV CARE: CardioVascular Care in PC Patients | recruiting | N/A | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06807294 | Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT) | active not recruiting | N/A | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02520713 | The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study | active not recruiting | — | 825 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial(SIERRA) | not yet recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07825051 | Healing Gardens: Leveraging Serious Games to Deliver Accessible Pain-CBT and Pharmacologic Support for Patients With Advanced Cancer Managing Pain | not yet recruiting | N/A | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04938232 | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | active not recruiting | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06609473 | Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors(CHEF) | recruiting | N/A | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07232043 | ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs(ACTIVATE) | recruiting | N/A | 70,000 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07821177 | Bladder Preservation or Cystectomy for MIBC | active not recruiting | Early Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03147287 | Palbociclib After CDK and Endocrine Therapy (PACE) | active not recruiting | Phase 2 | 220 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06202183 | Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial | recruiting | N/A | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04674267 | Resilience and Equity in Aging, Cancer, and Health (REACH)(REACH) | recruiting | N/A | 147 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06040125 | Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial | recruiting | N/A | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07513324 | Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) | not yet recruiting | Phase 2 | 116 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07548476 | Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy(ACE) | recruiting | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03414684 | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 78 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06907797 | Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing | recruiting | N/A | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07624513 | D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM | not yet recruiting | Phase 3 | 720 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT02981940 | A Study of Abemaciclib in Recurrent Glioblastoma | active not recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04724499 | Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy(CLARITY) | active not recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07601100 | Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma(IsaIberVD) | not yet recruiting | Phase 1 / Phase 2 | 88 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06488378 | Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04839614 | Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06940180 | Toripalimab With Chemotherapy for Sinus Cancer | recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07793994 | Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors | not yet recruiting | N/A | 130 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06152809 | CIML NK Cells With Venetoclax for AML | recruiting | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05587439 | Investigating Hereditary Risk In Thoracic Cancers (INHERIT)(INHERIT) | recruiting | — | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05759143 | Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing | active not recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07147023 | Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication(BRIDGE-SIC) | active not recruiting | N/A | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07662239 | Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention(AYA-ONE) | recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07735442 | BRIDGE-SIC Efficacy Trial | recruiting | N/A | 600 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03740334 | Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL | active not recruiting | Phase 1 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02282735 | Parental Decision-Making for Children With Relapsed Neuroblastoma | active not recruiting | — | 96 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04482244 | RCT of CBD for Anxiety in Advanced Breast Cancer | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | recruiting | Phase 2 | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06569147 | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06239220 | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | recruiting | Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07735624 | RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer(RECTIFY-1) | recruiting | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated unknownsource: clinicaltrials